{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:42:07Z","timestamp":1770068527032,"version":"3.49.0"},"reference-count":114,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ando.2012.09.002","type":"journal-article","created":{"date-parts":[[2012,10,15]],"date-time":"2012-10-15T15:00:52Z","timestamp":1350313252000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["New avenues for the pharmacological management of type 2 diabetes: An update"],"prefix":"10.1016","volume":"73","author":[{"given":"Thomas","family":"Cuny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Guerci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0005","doi-asserted-by":"crossref","first-page":"e32412","DOI":"10.1371\/journal.pone.0032412","article-title":"Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study","volume":"7","author":"Tiv","year":"2012","journal-title":"PLoS One"},{"issue":"9833","key":"10.1016\/j.ando.2012.09.002_bib0010","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/S0140-6736(12)60283-9","article-title":"Prediabetes: a high-risk state for diabetes development","volume":"379","author":"Tabak","year":"2012","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.ando.2012.09.002_bib0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1463-1326.2011.01449.x","article-title":"The role of dysregulated glucagon secretion in type 2 diabetes","volume":"13","author":"D\u2019Alessio","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.ando.2012.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/j.1365-2982.2010.01554.x","article-title":"Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis","volume":"22","author":"Edholm","year":"2010","journal-title":"Neurogastroenterol Motil"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"issue":"9548","key":"10.1016\/j.ando.2012.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ando.2012.09.002_bib0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.ando.2012.09.002_bib0040","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1046\/j.1464-5491.2001.00424.x","article-title":"No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose","volume":"18","author":"Vilsboll","year":"2001","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0055","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2337\/db09-1899","article-title":"Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?","volume":"59","author":"Meier","year":"2010","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0060","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1463-1326.2010.01317.x","article-title":"Pharmacological management of type 2 diabetes: the potential of incretin-based therapies","volume":"13","author":"Charbonnel","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2012.09.002_bib0070","first-page":"CD006423","article-title":"Glucagon-like peptide analogues for type 2 diabetes mellitus","volume":"10","author":"Shyangdan","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0075","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.clinthera.2006.05.006","article-title":"Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus","volume":"28","author":"Iltz","year":"2006","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0091270010367653","article-title":"Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers","volume":"51","author":"Pinelli","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"9683","key":"10.1016\/j.ando.2012.09.002_bib0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0090","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2012.09.002_bib0095","article-title":"Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"supplt 1","author":"Buse","year":"2011","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.ando.2012.09.002_bib0100","first-page":"503","article-title":"Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus","volume":"12","author":"Christensen","year":"2009","journal-title":"IDrugs"},{"issue":"9","key":"10.1016\/j.ando.2012.09.002_bib0105","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2010.03020.x","article-title":"Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial","volume":"27","author":"Ratner","year":"2010","journal-title":"Diabet Med"},{"issue":"6","key":"10.1016\/j.ando.2012.09.002_bib0110","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ando.2012.09.002_bib0115","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1463-1326.2012.01618.x","article-title":"Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)","volume":"14","author":"Seino","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ando.2012.09.002_bib0120","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2008-1518","article-title":"Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes","volume":"93","author":"Matthews","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ando.2012.09.002_bib0125","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2337\/dc11-1942","article-title":"Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)","volume":"35","author":"Raz","year":"2012","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0135","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1210\/jc.2011-3253","article-title":"Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial","volume":"97","author":"Henry","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9833","key":"10.1016\/j.ando.2012.09.002_bib0140","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/S0140-6736(12)60479-6","article-title":"Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial","volume":"379","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0150","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","article-title":"Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets","volume":"35","author":"DeVries","year":"2012","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0155","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1345\/aph.1M676","article-title":"Association of pancreatitis with glucagon-like peptide-1 agonist use","volume":"44","author":"Anderson","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00125-009-1515-4","article-title":"Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas","volume":"53","author":"Nachnani","year":"2010","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0165","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0170","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2337\/db11-0936","article-title":"The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species","volume":"61","author":"Nyborg","year":"2012","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ando.2012.09.002_bib0175","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","article-title":"Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation","volume":"151","author":"Bjerre Knudsen","year":"2010","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0180","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1210\/jc.2010-2318","article-title":"GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide","volume":"96","author":"Hegedus","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0185","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bcp.2011.11.028","article-title":"DPP-4 inhibitors in the treatment of type 2 diabetes","volume":"83","author":"Duez","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"10.1016\/j.ando.2012.09.002_bib0190","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1007\/s00125-012-2635-9","article-title":"Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors","volume":"55","author":"Scheen","year":"2012","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0195","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc10-1771","article-title":"Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase","volume":"34","author":"Willemen","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ando.2012.09.002_bib0200","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.amjcard.2012.01.398","article-title":"Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors","volume":"109","author":"Chrysant","year":"2012","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.ando.2012.09.002_bib0205","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0210","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00125-011-2365-4","article-title":"Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice","volume":"55","author":"Takeda","year":"2012","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsboll","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0220","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","article-title":"Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins","volume":"89","author":"Wood","year":"2003","journal-title":"Br J Nutr"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0230","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"issue":"9733","key":"10.1016\/j.ando.2012.09.002_bib0235","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(10)60749-0","article-title":"Dapagliflozin, an SGLT2 inhibitor, for diabetes","volume":"375","author":"Hanefeld","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ando.2012.09.002_bib0240","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"issue":"9733","key":"10.1016\/j.ando.2012.09.002_bib0245","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ando.2012.09.002_bib0250","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ando.2012.09.002_bib0255","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2012.09.002_bib0260","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","volume":"120","author":"List","year":"2011","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0265","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1742-1241.2012.02911.x","article-title":"Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial","volume":"66","author":"Henry","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.ando.2012.09.002_bib0270","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"issue":"17","key":"10.1016\/j.ando.2012.09.002_bib0275","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0280","doi-asserted-by":"crossref","first-page":"e30555","DOI":"10.1371\/journal.pone.0030555","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0285","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0290","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1185\/03007995.2012.689956","article-title":"Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study","volume":"28","author":"Nicolle","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0295","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1185\/03007995.2012.697053","article-title":"Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor","volume":"28","author":"Nyirjesy","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ando.2012.09.002_bib0560","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ando.2012.09.002_bib0300","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1089\/dia.2011.0012","article-title":"Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus","volume":"13","author":"Schwartz","year":"2011","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0305","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","article-title":"Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models","volume":"327","author":"Fujimori","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0310","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","article-title":"Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level","volume":"320","author":"Katsuno","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ando.2012.09.002_bib0315","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2012.06.027","article-title":"Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus","author":"Veltkamp","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ando.2012.09.002_bib0320","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1463-1326.2012.01624.x","article-title":"No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects","author":"Smulders","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.10187","article-title":"Pleiotropic effects of fatty acids on pancreatic beta-cells","volume":"194","author":"Haber","year":"2003","journal-title":"J Cell Physiol"},{"issue":"8","key":"10.1016\/j.ando.2012.09.002_bib0330","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/diabetes.48.8.1543","article-title":"Augmentation of Ca2+-stimulated insulin release by glucose and long-chain fatty acids in rat pancreatic islets: free fatty acids mimic ATP-sensitive K+ channel-independent insulinotropic action of glucose","volume":"48","author":"Komatsu","year":"1999","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0335","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0003-4266(04)95628-4","article-title":"Gluco-lipotoxicity of the pancreatic beta cell","volume":"65","author":"Poitout","year":"2004","journal-title":"Ann Endocrinol (Paris)"},{"issue":"Suppl. 2","key":"10.1016\/j.ando.2012.09.002_bib0340","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.2337\/db06-S003","article-title":"Fatty acid signaling in the beta-cell and insulin secretion","volume":"55","author":"Nolan","year":"2006","journal-title":"Diabetes"},{"issue":"6928","key":"10.1016\/j.ando.2012.09.002_bib0345","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ando.2012.09.002_bib0350","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.bbrc.2005.10.161","article-title":"GPR40 gene expression in human pancreas and insulinoma","volume":"338","author":"Tomita","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"1\u20132","key":"10.1016\/j.ando.2012.09.002_bib0355","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.mce.2006.09.013","article-title":"Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40","volume":"263","author":"Schnell","year":"2007","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"10.1016\/j.ando.2012.09.002_bib0360","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2337\/db08-0307","article-title":"Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion","volume":"57","author":"Edfalk","year":"2008","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ando.2012.09.002_bib0365","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bbrc.2004.11.120","article-title":"Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor","volume":"326","author":"Soga","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.ando.2012.09.002_bib0370","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1210\/en.2006-1608","article-title":"A role for beta-cell-expressed G-protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release","volume":"148","author":"Chu","year":"2007","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0375","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2337\/db08-1237","article-title":"GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell","volume":"58","author":"Lauffer","year":"2009","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0380","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/jpet.111.183772","article-title":"TAK-875, an orally available G-protein-coupled receptor 40\/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats","volume":"339","author":"Tsujihata","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0385","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/clpt.2012.43","article-title":"A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes","volume":"92","author":"Leifke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0390","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0091270011409230","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of the GPR40 Agonist TAK-875: Results From a Double-Blind, Placebo-Controlled Single Oral Dose Rising Study in Healthy Volunteers","volume":"52","author":"Naik","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0395","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1463-1326.2011.01525.x","article-title":"GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes","volume":"14","author":"Araki","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"9824","key":"10.1016\/j.ando.2012.09.002_bib0400","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(11)61879-5","article-title":"TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"379","author":"Burant","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0405","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.bmcl.2011.10.118","article-title":"AMG 837: a potent, orally bioavailable GPR40 agonist","volume":"22","author":"Houze","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.ando.2012.09.002_bib0410","doi-asserted-by":"crossref","first-page":"e27270","DOI":"10.1371\/journal.pone.0027270","article-title":"AMG 837: a novel GPR40\/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0415","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.bbrc.2010.10.015","article-title":"Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db\/db mice","volume":"402","author":"Yoshida","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ando.2012.09.002_bib0420","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.bbrc.2010.08.141","article-title":"AS1907417, a novel GPR119 agonist, as an insulinotropic and beta-cell preservative agent for the treatment of type 2 diabetes","volume":"400","author":"Yoshida","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0425","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bbrc.2010.08.097","article-title":"Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion","volume":"400","author":"Yoshida","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"10.1016\/j.ando.2012.09.002_bib0430","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1463-1326.2012.01587.x","article-title":"Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes","volume":"14","author":"Katz","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"7897","key":"10.1016\/j.ando.2012.09.002_bib0435","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(75)92375-2","article-title":"The essential role of glucagon in the pathogenesis of diabetes mellitus","volume":"1","author":"Unger","year":"1975","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0440","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1210\/en.2011-1499","article-title":"Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes","volume":"153","author":"Cryer","year":"2012","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.ando.2012.09.002_bib0445","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1463-1326.2011.01427.x","article-title":"Glucagon antagonism as a potential therapeutic target in type 2 diabetes","volume":"13","author":"Bagger","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0450","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2337\/db10-0426","article-title":"Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice","volume":"60","author":"Lee","year":"2011","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0455","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/157339911797415585","article-title":"The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach","volume":"7","author":"Folli","year":"2011","journal-title":"Curr Diabetes Rev"},{"issue":"11","key":"10.1016\/j.ando.2012.09.002_bib0460","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1007\/s001250100006","article-title":"Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans","volume":"44","author":"Petersen","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2012.09.002_bib0465","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1021\/jm300579z","article-title":"Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbo nyl]-beta-alanine (MK-0893) for the treatment of type II diabetes","author":"Xiong","year":"2012","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.ando.2012.09.002_bib0470","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","article-title":"Thiazolidinediones and PPARgamma agonists: time for a reassessment","volume":"23","author":"Cariou","year":"2012","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ando.2012.09.002_bib0475","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ando.2012.09.002_bib0565","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(09)60870-9","article-title":"Effect of the dual peroxisome proliferator-activated receptor-alpha\/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study","volume":"374","author":"Henry","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ando.2012.09.002_bib0480","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"Cariou","year":"2011","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ando.2012.09.002_bib0485","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db07-1318","article-title":"Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men","volume":"57","author":"Riserus","year":"2008","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ando.2012.09.002_bib0490","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI10843","article-title":"Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists","volume":"106","author":"Olefsky","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2012.09.002_bib0495","doi-asserted-by":"crossref","first-page":"936906","DOI":"10.1155\/2008\/936906","article-title":"The development of INT131 as a selective PPARgamma modulator: zpproach to a safer insulin sensitizer","volume":"2008","author":"Higgins","year":"2008","journal-title":"PPAR Res"},{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0500","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdiacomp.2010.06.006","article-title":"Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes","volume":"25","author":"Dunn","year":"2011","journal-title":"J Diabetes Complications"},{"issue":"7305","key":"10.1016\/j.ando.2012.09.002_bib0505","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Antidiabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"issue":"7365","key":"10.1016\/j.ando.2012.09.002_bib0510","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ando.2012.09.002_bib0515","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2174\/138161208784246153","article-title":"Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity","volume":"14","author":"Heilbronn","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0520","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00125-008-0999-7","article-title":"Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells","volume":"51","author":"Ortis","year":"2008","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ando.2012.09.002_bib0525","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2165\/00003495-199753010-00007","article-title":"Diacerein","volume":"53","author":"Spencer","year":"1997","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ando.2012.09.002_bib0530","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.joca.2009.10.006","article-title":"Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Bartels","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"issue":"7","key":"10.1016\/j.ando.2012.09.002_bib0535","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc11-0357","article-title":"Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial","volume":"34","author":"Ramos-Zavala","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2012.09.002_bib0540","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/dc11-0357","article-title":"Comment on: Ramos-Zavala et al. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial","volume":"34","author":"Tobar","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ando.2012.09.002_bib0545","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1210\/en.2011-0249","article-title":"Diacerhein improves glucose tolerance and insulin sensitivity in mice on a high-fat diet","volume":"152","author":"Tobar","year":"2011","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.ando.2012.09.002_bib0550","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.ando.2012.09.002_bib0555","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1-receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"Larsen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2012.09.002_bib0570","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-152-6-201003160-00004","article-title":"The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial","volume":"152","author":"Goldfine","year":"2010","journal-title":"Ann Intern Med"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426612011675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426612011675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:46:11Z","timestamp":1757717171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426612011675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":114,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0003426612011675"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2012.09.002","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New avenues for the pharmacological management of type 2 diabetes: An update","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2012.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}